Navigation Links
Divine Skin Rolls Out Polaris API Solution 9: A New Technology for Physicians
Date:11/9/2011

MIAMI BEACH, Fla., Nov. 9, 2011 /PRNewswire/ -- Biotech developer Divine Skin Inc. (OTC Bulletin Board: DSKX) which has been expanding the topical hair-growth segment, is rolling out that market's newest, most potent, only customizable system, Polaris API Solution 9, to be supplied by physicians for treatment through multiple methods of action.

With well-established materials like minoxidil sulfate, finasteride, alfatradiol, and other active ingredients, Polaris API Solution 9 is the most complete solution that can be used for hair loss, either by prescription or over the counter configured to the individual needs of the patient by physicians. The current sales leader contains only 5% minoxidil in a standard carrier.

"We are launching a new category," declared CEO Daniel Khesin, speaking on a conference call with investors. "We expect this line to change the game and to offer a powerful new tool for dermatologists that can really make a difference in their approach to treatment."

Half of all men will experience some hair loss by age 50, and they can only purchase the customized Polaris product through physicians, who can create the potent mix of active pharmaceutical ingredients (API).

Divine Skin, which posted revenue of $5.4 million in 2010 — up 55 percent over the previous year — creates a major new revenue stream with Polaris API Solution 9, and stockholders expect to benefit for several years.

In published clinical trials, each major component of the new API — minoxidil sulfate, finasteride, and alfatradiol — has proven to inhibit androgenic alopecia (male pattern baldness) effectively. The system also includes other auxiliary agents like apple polyphenol, copper peptides, nutrients, and conditioners to enhance the formula further.

"With very few options available," says Khesin, "Polaris API Solution 9
'/>"/>

SOURCE Divine Skin Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Divine Skin Posts Record Sales for 2010: Up 55% Over 2009
2. Divine Skin Announces Four Deals for Explosive Distribution Growth
3. First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin
4. Robin Powell Becomes President at Biotech Leader Divine Skin (DSKX)
5. Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil
6. Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010
7. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
8. Rice rolls out new nanocars
9. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
10. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
11. Polaris Enrolls First Patient in Phase 2 Clinical Trial of ADI-PEG 20 for the Treatment of Malignant Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... New Jersey , 27 avril ... de découverte médicamenteuse spécialisée dans le ... destinés à soigner les infections bactériennes ... la présentation de données prouvant les ... le TXA709, dans la lutte contre ...
(Date:4/27/2015)... Corporation (NYSE: HAE ) today reported revenue ... million, down 6%.  Excluding currency impact, revenue was ... a fourth quarter GAAP net loss of $2.9 ... exclusive of transformation, restructuring and deal amortization expenses ... adjusted earnings per share were $0.47, up 2%. ...
(Date:4/27/2015)... 27, 2015 tru Shrimp™ Systems announced ... Texas A&M University for the exclusive worldwide rights to ... raceway systems. The license agreement for the patented technology, ... to countries such as China, Taiwan, France, Germany, Italy, ... “We have had inquires from all over the world ...
(Date:4/25/2015)... Madison, WI (PRWEB) April 25, 2015 ... on April 29th: Analyzing Kinase Inhibitor Residence Times using ... , Analysis of inhibitor residence times is increasingly being ... the target can result in improved efficacy, increased therapeutic ... can be determined using immobilized ligand methods such surface ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 31
... SAN DIEGO, Dec. 16, 2010 Gen-Probe Incorporated (Nasdaq: ... has acquired GTI Diagnostics, a privately held specialty diagnostics ... coagulation markets, for $53 million in cash. ... private equity firm, and from individual investors who include ...
... Conn., Dec. 15, 2010 HistoRx announces that Jack ... of Directors.  As the former President and CEO of ... company, he is an acknowledged diagnostic industry expert. ... Chairman of the Board at Dianon Systems, a leading ...
... performance of a brain-machine interface designed to help paralyzed subjects ... of a robotic arm providing sensory feedback, a new study ... translate brain activity into the movement of a computer cursor ... humans. But in these early systems, vision was the only ...
Cached Biology Technology:Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash 2Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash 3Jack Davis, Diagnostics Industry Executive, Joins the HistoRx Board of Directors 2Robot arm improves performance of brain-controlled device 2Robot arm improves performance of brain-controlled device 3
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 11 The following statement was,issued today by ... Affairs:, Good afternoon. I want to thank ... hospitality during our visit and for their,dedication to ... Germany., The cooperation between our two countries ...
... the University of Wisconsin School of Medicine and Public Health ... the way digits are formed. Studying the embryonic chick ... that explains how digits grow and why each digit is ... the Proceedings of the National Academy of Sciences Online Early ...
... startling discovery by scientists at the Carnegie Institution puts ... biological process on Earth. Photosynthesis by plants, algae, and ... food from sunlight, and in the process these organisms ... by Arthur Grossman and colleagues*+ reported in Biochimica et ...
Cached Biology News:Remarks Prepared for Delivery By Attorney General Michael B. Mukasey At the Ministerial Press Conference 2Wisconsin researchers describe how digits grow 2Wisconsin researchers describe how digits grow 3New twist on life's power source 2New twist on life's power source 3